Irradiation-induced up-regulation of Fas in esophageal squamous cell carcinoma is not accompanied by Fas ligand-mediated apoptosis

Journal of Surgical Oncology

Volumn 71, Issue 2, 1999, Pages 91-96

  Rigberg, David A ^a   Centeno, Joseph ^a   Kim, Frances S ^a   Ke, Bibo ^a   Swenson, Kim ^a   Maggard, Melinda ^a   Mcfadden, David W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fas CD95 APO 1; p53; Transduction

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; COMPLEMENTARY DNA; CYCLOHEXIMIDE; FAS ANTIGEN; FAS LIGAND; MONOCLONAL ANTIBODY;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; GAMMA IRRADIATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ANTIGENS, CD95; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FAS LIGAND PROTEIN; GENES, P53; HUMANS; LIGANDS; MEMBRANE GLYCOPROTEINS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0033042166     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199906)71:2<91::AID-JSO6>3.0.CO;2-7     Document Type: Article

References (25)

1. Itoh N, Yonehara S, Ishii A, et al.: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-243.
2. Meterissian SH, Kontogiannea M, Po J, et al.: Apoptosis induced in human colorectal carcinoma by anti-fas antibody. Ann Surg Oncol 1997;4:169-175.
3. Suda T, Takahashi T, Golstein P, et al.: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-1178.
4. Chinnaiyan AM, O'Rourke K, Tewari M, et al.: FADD, a novel death-domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-512.
5. Owen-Schaub L, Meterissian S, Ford RJ: Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin. J Immunother 1993;14:234-241.
6. Moller P, Koretz K, Leithauser F, et al.: Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 1994;57:371-377.
7. Gutierrez-Steil C, Wrone-Smith T, Sun X, et al.: Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L). J Clin Invest 1998; 101:33-39.
8. Shiraki K, Tsuji N, Shioda T, et al.: Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997;94:6420-6425.
9. Walker PR, Saas P, Dietrich PY: Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back. J Immunol 1997; 158:4521-4524.
10. Nagata S, Golstein P: The Fas death factor. Science 1995;267: 1449-1456.
11. WILD-TYPE cancer cells treated with ionizing radiation. Int J Cancer 1997;73:757-762.
12. L depends on normal p53 function. Oncogene 1996;13:2287-2293.
13. Bhansali MS, Patil PK, Badwe RA, et al.: Historical control bias; adjuvant chemotherapy in esophageal cancer. Dis Esophagus 1997;10:51-54.
14. Stein H: Esophageal cancer: Screening and surveillance. Dis Esophagus 1996;9(Suppl 1):3-19.
15. Rigberg DA, Kim FS, Blinman TA, et al.: p21 expression is increased by irradiation in esophageal squamous cell carcinoma. J Surg Res 1998;76:137-142.
16. Tanaka H, Shibagaki I, Shimada Y, et al.: Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: Increased frequency and different spectrum of mutations from primary tumors. Int J Cancer 1996;65:372-376.
17. Owen-Schaub LB, Radinsky R, Kruzel E, et al.: Anti-Fas on nonhematopoietic tumors: Levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 1994;54: 1580-1586.
18. Swenson KM, Ke B, Wang T, et al.: Fas ligand gene transfer to renal allografts in rats. Transplantation 1998;65:155-160.
19. Williams BA, Makrigiannis AP, Blay J, et al.: Treatment of the P815 murine mastocytoma with cisplatin or etoposide upregulates cell-surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody-mediated cytotoxicity and to lysis by anti-CD3-activated killer-T cells. Int J Cancer 1997;73:416-423.
20. Furukawa F, Kanauchi H, Wakita H, et al.: Spontaneous autoimmune skin lesions of MRL/n mice: Autoimmune disease-prone genetic background in relation to Fas-defect MRL/1pr mice. J Invest Dermatol 1996;107:95-100.
21. Landowski TH, Qu N, Buyuksal I, et al.: Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997;90:4266-4270.
22. Pensati L, Costanzo A, Ianni A, et al.: Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Gastroenterology 1997;113:1384-1389.
23. Suzuki N, Ichino M, Mihara S, et al.: Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:344-353.
24. Hughes DP, Crispe IN: A naturally occurring soluble isoform of murine Fas generated by alternative splicing. J Exp Med 1995; 182:1395-1401.
25. Kim PK, Dutra AS, Chandrasekharappa SC, et al.: Genomic structure and mapping of human FADD, an intracellular mediator of lymphocyte apoptosis. J Immunol 1996;157:5461-5466.